Ono Pharmaceutical has filed a patent for a drug containing a compound with ABHD6 inhibitory activity for preventing or treating diseases associated with ABHD6. The compound of formula (I-A) or its salt is claimed to have potent ABHD6 inhibitory activity. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ono Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ono Pharmaceutical, Peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240010658A1) discloses a series of compounds and pharmaceutical compositions for treating diseases associated with ABHD6. The compounds are represented by specific chemical formulas and can be used in the treatment and prevention of various conditions, including pain, neurological diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, and malignant tumors. The patent claims cover the compounds themselves, as well as their use in pharmaceutical compositions as active ingredients.

The pharmaceutical compositions described in the patent can be administered with a pharmaceutically acceptable carrier and are specifically identified as ABHD6 inhibitors. These compositions are intended for the treatment of diseases linked to ABHD6, such as pain associated with osteoarthritis, cancer pain, neuropathic pain, and various other conditions. The patent also includes methods for preventing and treating ABHD6-related diseases using the disclosed compounds and compositions. Additionally, the patent covers the use of these compounds in combination with other drugs commonly used for pain management, such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioid drugs. Overall, the patent provides a comprehensive overview of the potential applications of the disclosed compounds in the field of pharmaceuticals for ABHD6-related conditions.

To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies